Abstract
If RNA interference is to have any impact on cancer therapy, it will have to pass three tests. It will need to specifically target tumor cells, effectively stop their growth, and do so with few side effects. Now a team of investigators is reporting it has passed all three tests in a mouse model of Ewing's sarcoma, a particularly aggressive cancer that strikes mainly children.